Moreover, in that study, PD-L1 was shown to inhibit CAR-T cells, but not CAR-T EVs both in vitro and in vivo, suggesting a better resilience of EVs to tumor immune evasion strategies. This evidence concerns the gene CD274 and neoplasm.